2024-03-29T05:12:17Zhttps://eprints.lib.hokudai.ac.jp/dspace-oai/requestoai:eprints.lib.hokudai.ac.jp:2115/868672022-11-17T02:08:08Zhdl_2115_20048hdl_2115_140In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickensFujisawa, SotaroMurata, ShiroTakehara, MasakiAoyama, JuliaMorita, AyuIsezaki, MasayoshiWin, Shwe YeeAriizumi, TakumaSato, TakumiOishi, EijiTaneno, AkiraMaekawa, NaoyaOkagawa, TomohiroIchii, OsamuKonnai, SatoruOhashi, KazuhikoPoultry red miteAdipocyte plasma membrane-associated proteinVaccineDg-APMAPDermanyssus gallinae649The poultry red mite (Dermanyssus gallinae; PRM) is a blood-sucking ectoparasite of chickens that is a threat to poultry farming worldwide and significantly reduces productivity in the egg-laying industry. Chemical acaricides that are widely used in poultry farms for the prevention of PRMs are frequently ineffective due to the emergence of acaricide-resistant PRMs. Therefore, alternative control methods are needed, and vaccination is a promising strategy for controlling PRMs. A novel adipocyte-plasma membrane-associated protein-like molecule (Dg-APMAP) is highly expressed in blood-fed PRMs according to a previous RNA sequencing analysis. Here, we attempted to identify the full sequence of DgAPMAP, study its expression in different life stages of PRMs, and evaluate its potential as a vaccine antigen. Dg-APMAP mRNA was expressed in the midgut and ovaries, and in all life stages regardless of feeding states. Importantly, in vitro feeding of PRMs with plasma derived from chickens immunized with the recombinant protein of the extracellular region of Dg-APMAP significantly reduced their survival rate in nymphs and adults, which require blood meals. Our data suggest that the host immune responses induced by vaccination with Dg-APMAP could be an effective strategy to reduce the suffering caused by PRMs in the poultry industry. (c) 2021 Elsevier Ltd. All rights reserved.ElsevierJournal Articleapplication/pdfapplication/vnd.openxmlformats-officedocument.presentationml.presentationhttp://hdl.handle.net/2115/86867https://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/86867/1/Manuscript.pdfhttps://eprints.lib.hokudai.ac.jp/dspace/bitstream/2115/86867/2/Supplementary%20materials.pptx0264-410XVaccine3941605760662021-10-01enginfo:doi/10.1016/j.vaccine.2021.08.104© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/author